A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Chantal Mathieu, MD
University Hospital of Leuven, Clinical and Experimental Endocrinology
Principal Investigator - Kevan Herold, MD
Yale Center for Clinical Investigation; Yale University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uz Brussel
Brussels, Belgium
- Uz Antwerpen
Edegem, Belgium
- Uz Leuven
Leuven, Belgium
- University of Alabama, Birmingham
Birmingham, Alabama, United States
- University of California, San Francisco
San Francisco, California, United States
- Coastal Metabolic Research Centre
Ventura, California, United States
- University of Colorado
Aurora, Colorado, United States
- Yale Center for Clinical Investigation
New Haven, Connecticut, United States
- University of Miami
Miami, Florida, United States
- University of South Florida
Tampa, Florida, United States
- Barry J Reiner, Md, Llc
Baltimore, Maryland, United States
- University of Minnesota Health
Minneapolis, Minnesota, United States
- University of Missouri-Kansas City School of Medicine
Kansas City, Missouri, United States
- Sanford Children'S Specialty Clinic
Sioux Falls, South Dakota, United States
- University Diabetes and Endocrine Consultants
Chattanooga, Tennessee, United States
- Texas Diabetes & Endocrinology, P.A.
Austin, Texas, United States
- Research Institute of Dallas
Dallas, Texas, United States
- Benaroya Research Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Oct 2018
- Primary completion
- 13 Oct 2021
- Completion
- 13 Oct 2021
- Last update posted
- 1 Feb 2023
- Registered enrollment
- 45
- Registry id
- NCT03751007
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.